Cargando…
The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients
BACKGROUND: The effect of thiopurine immunomodulators on health-related quality of life (HRQoL) in patients with inflammatory bowel disease (IBD) has been controversial. The aims were to evaluate the HRQoL in patients with IBD treated with thiopurines and assess the short- and long-term impacts of t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846867/ https://www.ncbi.nlm.nih.gov/pubmed/20196836 http://dx.doi.org/10.1186/1471-230X-10-26 |
_version_ | 1782179507010011136 |
---|---|
author | Bastida, Guillermo Nos, Pilar Aguas, Mariam Beltrán, Belén Iborra, Marisa Ortiz, Vicente Garrigues, Vicente Estevan, Rafael Ponce, Julio |
author_facet | Bastida, Guillermo Nos, Pilar Aguas, Mariam Beltrán, Belén Iborra, Marisa Ortiz, Vicente Garrigues, Vicente Estevan, Rafael Ponce, Julio |
author_sort | Bastida, Guillermo |
collection | PubMed |
description | BACKGROUND: The effect of thiopurine immunomodulators on health-related quality of life (HRQoL) in patients with inflammatory bowel disease (IBD) has been controversial. The aims were to evaluate the HRQoL in patients with IBD treated with thiopurines and assess the short- and long-term impacts of the treatment on HRQoL. METHODS: Ninety-two consecutive patients who started treatment with thiopurines were prospectively included. Evaluation of HRQoL was performed at months 0, 6, and 12 using two questionnaires, the Short-Form Health Survey (SF-36) and the Inflammatory Bowel Disease Questionnaire (IBDQ). RESULTS: Baseline score of IBDQ was 4,6, range (2,31-6,84), with an impairment of the five dimensions of HRQoL compared with inactive patients. Results obtained in 8 dimensions of SF-36 showed worse HRQoL than Spanish general population. At 6 months patients had a significant improvement in overall IBDQ score -5,8 (1,58 -6,97)- and also in all IBDQ dimensions. All the 8 dimensions of SF-36 obtained a significant improvement. At twelve months score of IBDQ was 6,1, range (2,7-6,98), with improvement in all dimensions compared with baseline and 6 months. SF-36 showed a similar significant improvement in all subscales. CONCLUSIONS: Thiopurine immunomodulators alone or with other treatments have a positive and long lasting impact on HRQoL of IBD patients. |
format | Text |
id | pubmed-2846867 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-28468672010-03-30 The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients Bastida, Guillermo Nos, Pilar Aguas, Mariam Beltrán, Belén Iborra, Marisa Ortiz, Vicente Garrigues, Vicente Estevan, Rafael Ponce, Julio BMC Gastroenterol Research Article BACKGROUND: The effect of thiopurine immunomodulators on health-related quality of life (HRQoL) in patients with inflammatory bowel disease (IBD) has been controversial. The aims were to evaluate the HRQoL in patients with IBD treated with thiopurines and assess the short- and long-term impacts of the treatment on HRQoL. METHODS: Ninety-two consecutive patients who started treatment with thiopurines were prospectively included. Evaluation of HRQoL was performed at months 0, 6, and 12 using two questionnaires, the Short-Form Health Survey (SF-36) and the Inflammatory Bowel Disease Questionnaire (IBDQ). RESULTS: Baseline score of IBDQ was 4,6, range (2,31-6,84), with an impairment of the five dimensions of HRQoL compared with inactive patients. Results obtained in 8 dimensions of SF-36 showed worse HRQoL than Spanish general population. At 6 months patients had a significant improvement in overall IBDQ score -5,8 (1,58 -6,97)- and also in all IBDQ dimensions. All the 8 dimensions of SF-36 obtained a significant improvement. At twelve months score of IBDQ was 6,1, range (2,7-6,98), with improvement in all dimensions compared with baseline and 6 months. SF-36 showed a similar significant improvement in all subscales. CONCLUSIONS: Thiopurine immunomodulators alone or with other treatments have a positive and long lasting impact on HRQoL of IBD patients. BioMed Central 2010-03-02 /pmc/articles/PMC2846867/ /pubmed/20196836 http://dx.doi.org/10.1186/1471-230X-10-26 Text en Copyright ©2010 Bastida et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Bastida, Guillermo Nos, Pilar Aguas, Mariam Beltrán, Belén Iborra, Marisa Ortiz, Vicente Garrigues, Vicente Estevan, Rafael Ponce, Julio The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients |
title | The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients |
title_full | The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients |
title_fullStr | The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients |
title_full_unstemmed | The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients |
title_short | The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients |
title_sort | effects of thiopurine therapy on health-related quality of life in inflammatory bowel disease patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846867/ https://www.ncbi.nlm.nih.gov/pubmed/20196836 http://dx.doi.org/10.1186/1471-230X-10-26 |
work_keys_str_mv | AT bastidaguillermo theeffectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients AT nospilar theeffectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients AT aguasmariam theeffectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients AT beltranbelen theeffectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients AT iborramarisa theeffectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients AT ortizvicente theeffectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients AT garriguesvicente theeffectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients AT estevanrafael theeffectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients AT poncejulio theeffectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients AT bastidaguillermo effectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients AT nospilar effectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients AT aguasmariam effectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients AT beltranbelen effectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients AT iborramarisa effectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients AT ortizvicente effectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients AT garriguesvicente effectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients AT estevanrafael effectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients AT poncejulio effectsofthiopurinetherapyonhealthrelatedqualityoflifeininflammatoryboweldiseasepatients |